Making News

Epigenetic signatures could differentiate highly aggressive and benign forms of breast cancer

Epigenetic ‘signatures’ that could help clinicians tell the difference between highly aggressive and benign forms of triple-negative breast cancer have been identified by Garvan researchers. Triple-negative breast cancers make up 15-20% of all breast cancers and lack any of the three receptors (oestrogen, progesterone or HER2) that would make them responsive to targeted drugs. The first of its kind study used epigenetics (the study of information which determines how DNA is organised in the cell, which genes are expressed and how genes control development) to compare the DNA methylome (modifications in the genome) of breast cancer patients with that of healthy individuals. This study indicates that selected groups of patients could be tracked over time, monitoring how they respond to different treatments.

Most in-depth analysis to date identifies four pancreatic cancer genome sub-types

The most in-depth analysis of 100 pancreatic cancer genomes to date has revealed four subtypes that may help guide future patient treatment. The study, which was led by Garvan’s Professor Andrew Biankin, was published in Nature. Using whole genome sequencing (utilising state-of-the-art technology at Garvan), the team revealed broad patterns of ‘structural variation’ or change, previously invisible when sequencing only protein-coding genes (around 2% of the genome). With the benefit of a global view, four kinds of genomic rearrangement were detected in the new study, including ‘stable’, ‘locally rearranged’, ‘scattered’ and ‘unstable’. In some cases – notably ‘unstable’ genomes, which show defective DNA repair mechanisms – effective treatments suggested themselves.

Scientists create food additive that will make you feel fuller

A food-additive designed to make people feel fuller has been tested by UK and Australian clinicians, and shown to be effective at preventing weight gain in overweight volunteers. Known as ‘inulin-propionate ester’ (IPE), the additive combines ‘inulin’, a naturally occurring fibre, with propionate, a normal by-product of fibre fermentation by intestinal bacteria, and delivers much larger quantities of propionate than people can acquire with a normal diet. This is desirable because propionate stimulates the gut to release hormones that act on the brain to reduce hunger.
Respect and learning opportunities make Garvan stand out.

Garvan welcomes new Deputy Director, Professor Chris Goodnow FAA FRAS

Garvan is delighted to announce that distinguished immunologist and molecular geneticist, Professor Chris Goodnow FAA FRAS, has now taken up his position as the Institute’s Deputy Director.

Professor Goodnow has also assumed The Bill and Patricia Ritchie Foundation Chair and is setting up a lab in Immunogenomics to investigate the underlying genetic causes of immune disorders, particularly autoimmune diseases (which attack the ‘self’).

Goodnow is current President of the Australasian Society for Immunology. His research has been recognised by a number of awards and honours, including: American Association of Immunologists (AAI) Plarrmening Investigator Award; AAI Distinguished Lecturer; Australasian Society for Immunology Burnet Orator; Gottschalk Medal; Health Minister’s Prize; Centenary Medal; Ramaciotti Medal; GSK Award for Research Excellence; Fellowship of the Australasian Academy of Science; Fellowship of the Royal Society, and Membership of the US National Academy of Sciences.

Immediately prior to joining Garvan, Goodnow led the Division of Immunology at the John Curtin School of Medical Research, Australian National University (ANU). He joined ANU in 1997 as Professor and Director of the Medical Genome Centre, leading its development into a Major National Research Facility – the Australian Phenomics Facility.

Executive Director of Garvan, Professor John Mattick AO FAA FRCPA, is very pleased about the arrival of his new Deputy. “Professor Goodnow is one of Australia’s most outstanding scientists, who will greatly strengthen Garvan’s pre-eminence in human genomics,” he said.

“PROFESSOR GOODNOW IS ONE OF AUSTRALIA’S MOST OUTSTANDING SCIENTISTS, WHO WILL GREATLY STRENGTHEN GARVAN’S PRE-EMINENCE IN HUMAN GENOMICS.”

From the CEO

The first few months of 2015 have been as busy as ever – particularly with the recent appointment of distinguished immunologist and molecular geneticist, Professor Chris Goodnow FAA FRAS, as the Institute’s Deputy Director.

As you will see from the profile in this issue of Breakthrough, Professor Goodnow has, throughout his career, been fascinated by how the immune system makes its decisions. In particular, how it distinguishes between ‘self’ and ‘non-self’.

Such a major appointment has only been made possible thanks to the wonderful generosity of The Bill and Patricia Ritchie Foundation, a benefactor to Garvan for many years. In this case we are very grateful to sisters, Julia and Ruth Ritchie for a wonderful gift to endow a Chair in memory of their late parents, Bill and Patricia Ritchie.

As you will read, Professor Goodnow has been recognised as an international leader in his field, receiving many prestigious Australian and international awards and honours. Garvan has a reputation as a leading research institute, and this is reflected by the number of excellent scientists joining our ranks, as well as the continued local and international recognition our researchers receive.

For instance:
- Associate Professor Stuart Tangye, recently appointed head of Garvan’s Immunology Division, has been awarded a prestigious scholarship by the Australian American Fulbright Commission, an educational and cultural exchange program underwritten by the Australian and US Governments.
- The American Association of Immunologists (AAI) has selected Garvan’s Professor Jonathan Sprent FAA FRAS to be the 2015 recipient of the AAI Lifetime Achievement Award.
- Head of Garvan’s pancreatic cancer research, Professor Andrew Biankin was recently elected as a Fellow of the Royal Society of Edinburgh.

Garvan is proud to be home to so many gifted and visionary scientists. It is entirely with your help that we can continue to seek and retain the best-of-the-best, maintaining Garvan’s tradition of research excellence.

I hope you enjoy reading about Professor Goodnow (and our other updates) in this issue. Thank you for your ongoing support.

From the CEO

The first few months of 2015 have been as busy as ever – particularly with the recent appointment of distinguished immunologist and molecular geneticist, Professor Chris Goodnow FAA FRAS, as the Institute’s Deputy Director.

As you will see from the profile in this issue of Breakthrough, Professor Goodnow has, throughout his career, been fascinated by how the immune system makes its decisions. In particular, how it distinguishes between ‘self’ and ‘non-self’.

Such a major appointment has only been made possible thanks to the wonderful generosity of The Bill and Patricia Ritchie Foundation, a benefactor to Garvan for many years. In this case we are very grateful to sisters, Julia and Ruth Ritchie for a wonderful gift to endow a Chair in memory of their late parents, Bill and Patricia Ritchie.

As you will read, Professor Goodnow has been recognised as an international leader in his field, receiving many prestigious Australian and international awards and honours. Garvan has a reputation as a leading research institute, and this is reflected by the number of excellent scientists joining our ranks, as well as the continued local and international recognition our researchers receive.

For instance:
- Associate Professor Stuart Tangye, recently appointed head of Garvan’s Immunology Division, has been awarded a prestigious scholarship by the Australian American Fulbright Commission, an educational and cultural exchange program underwritten by the Australian and US Governments.
- The American Association of Immunologists (AAI) has selected Garvan’s Professor Jonathan Sprent FAA FRAS to be the 2015 recipient of the AAI Lifetime Achievement Award.
- Head of Garvan’s pancreatic cancer research, Professor Andrew Biankin was recently elected as a Fellow of the Royal Society of Edinburgh.

Garvan is proud to be home to so many gifted and visionary scientists. It is entirely with your help that we can continue to seek and retain the best-of-the-best, maintaining Garvan’s tradition of research excellence.

I hope you enjoy reading about Professor Goodnow (and our other updates) in this issue. Thank you for your ongoing support.

From the CEO

The first few months of 2015 have been as busy as ever – particularly with the recent appointment of distinguished immunologist and molecular geneticist, Professor Chris Goodnow FAA FRAS, as the Institute’s Deputy Director.

As you will see from the profile in this issue of Breakthrough, Professor Goodnow has, throughout his career, been fascinated by how the immune system makes its decisions. In particular, how it distinguishes between ‘self’ and ‘non-self’.

Such a major appointment has only been made possible thanks to the wonderful generosity of The Bill and Patricia Ritchie Foundation, a benefactor to Garvan for many years. In this case we are very grateful to sisters, Julia and Ruth Ritchie for a wonderful gift to endow a Chair in memory of their late parents, Bill and Patricia Ritchie.

As you will read, Professor Goodnow has been recognised as an international leader in his field, receiving many prestigious Australian and international awards and honours. Garvan has a reputation as a leading research institute, and this is reflected by the number of excellent scientists joining our ranks, as well as the continued local and international recognition our researchers receive.

For instance:
- Associate Professor Stuart Tangye, recently appointed head of Garvan’s Immunology Division, has been awarded a prestigious scholarship by the Australian American Fulbright Commission, an educational and cultural exchange program underwritten by the Australian and US Governments.
- The American Association of Immunologists (AAI) has selected Garvan’s Professor Jonathan Sprent FAA FRAS to be the 2015 recipient of the AAI Lifetime Achievement Award.
- Head of Garvan’s pancreatic cancer research, Professor Andrew Biankin was recently elected as a Fellow of the Royal Society of Edinburgh.

Garvan is proud to be home to so many gifted and visionary scientists. It is entirely with your help that we can continue to seek and retain the best-of-the-best, maintaining Garvan’s tradition of research excellence.

I hope you enjoy reading about Professor Goodnow (and our other updates) in this issue. Thank you for your ongoing support.
Prostate cancer is the second most common cancer in men. It is often considered as a ‘less aggressive’ cancer, and good treatments are available for ‘localised’ or ‘early’ prostate cancer.

However, in 40 per cent of patients, the cancer will spread to other organs, mainly the skeleton. This is referred to as ‘advanced’ prostate cancer and is a lot more difficult to treat. We don’t know why, but some cancer cells spread to the bone and remain inactive for a very long time – months, or even many years. Understanding why dormant prostate cancer cells are hibernating and hiding away in the bone, and what triggers their activation is important.

Understanding how prostate cancers develop in the skeleton, and why inactive cells suddenly become active is important if we are to develop new approaches to treatment.

In this article, Professor Peter Croucher, head of Garvan’s Osteoporosis and Bone Biology division explains the new ProMis (Prostate Cancer Metastasis) project, and what it hopes to achieve.

**What is ProMis hoping to achieve?**

Our main goal is to test the hypothesis that: ‘Prostate cancer cells stay in an inactive state in the skeleton and can be released from inactivity to form tumours in the bone due to changes in the cell or the cell’s surrounding’.

ProMis hopes to find the answer to three big questions:

1. Where do cancer cells go in the skeleton?
2. What is their genetic make-up when inactive and active?
3. How are they activated? By specific properties from within the cell, or by changes to the bone environment in which they reside?

The skeleton is a dynamic organ that is constantly renewing itself. Bone cells known as ‘osteoblasts’ help build new bone, while those known as ‘osteoclasts’ break down bone.

We believe that something changes within the bone microenvironment to activate the dormant cancer cells. That change may be driven by a cancer cell’s interaction with bone-destructing osteoclasts, or its interaction with immune cells.

The ProMis team will be tracking the effects of bone-active drugs, such as bisphosphonates or the antibody ‘denosumab’, which prevent osteoclasts from breaking down bone. We suspect that blocking the action of osteoclasts might stop cancer cells from being activated. The most pertinent question for us is whether bone-active drugs can retain cells in a dormant state indefinitely, or for a long period of time, to stop them being activated and forming tumours.

**What is the biggest challenge for ProMis?**

Understanding the conditions within the bone microenvironment that trigger metastasis has been technically impossible until now. Once a cancer spreads to bone, it becomes notoriously difficult to treat, so it’s important for us to establish the exact course of critical molecular events between a cancer cell’s arrival and its activation.

The difficulty we have encountered until now has been actually finding the cancer cells before they become active, because there tend to be so few, and they can lodge almost anywhere in the skeleton. We now have tools that allow us to find inactive cells in an experimental model system, and we’re applying that technology to prostate cancer.

Bringing together researchers from different backgrounds, each with diverse skills and proven track records in their areas of expertise will make tackling this problem more achievable.

**The ProMis team**

ProMis is a unique international collaboration among highly-experienced prostate cancer investigators, as well as experts from other fields including bone biology, breast cancer, transcriptomics (the study of the complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell) and genomics.

**Organisations represented on the ProMis team include:**

- The Garvan Institute of Medical Research including Garvan facilities: - The Kinghorn Cancer Centre - Kinghorn Centre for Clinical Genomics - Garvan Institute Small Animal Imaging Facility - Department of Surgery, University of Melbourne, Royal Melbourne Hospital - Department of Biochemistry, La Trobe University (Melbourne) - J.Craig Venter Institute (San Diego, USA)
- Institute of Precision Medicine of New York, Presbyterian Hospital and Weil Cornell Medical College (New York, USA)
- University of California, San Diego Moores Cancer Center (San Diego, USA)
- The Mellanby Centre for Bone Research, University of Sheffield (Sheffield, UK)
- Nuffield Department of Surgical Sciences and Nuffield Department of Orthopaedics, Rheumatology and Surgical Sciences (Oxford, UK)
- Institute of Molecular Medicine, Hospital de Santa Maria (Lisbon, Portugal)
- Australian Prostate Cancer Research Centre – New South Wales

**Training the next generation of prostate cancer researchers**

ProMis will also train the next generation of prostate cancer researchers. We will create an innovative, visionary and world-class training environment to develop junior investigators and mid-career researchers, both non-clinical and clinical, within the research program.

A Training Scheme, involving the active participation of each centre via workshops, exchange visits and mentorships, will strengthen the research network, as well as fostering collaborations and furthering the long-term sustainability and likelihood of successful outcomes.

Strong emphasis will be placed on mentoring co-Team Leaders, with the aim that they will develop more senior and independent (self-funded) research and assume leadership roles.

PhD students working on ProMis will have added benefits, beyond their postgraduate training, including attending workshops and a conference, visiting partner laboratories and the chance to network with senior researchers in the field.

The three centres in Australia will each host one training workshop, to which all members of ProMis will be invited. Each will be interdisciplinary in nature, addressing laboratory-based technologies as well as clinical issues.

**The future of ProMis**

We were the successful recipients of one of two 2014 Movember Revolutionary Team Awards from the Prostate Cancer Foundation of Australia. Without this funding, the ProMis project would not be possible.

This award will support the core of the ProMis project over a period of three years. However, it doesn’t cover all the costs related to the ProMis study.

Further funds are needed to cover these additional costs, and to secure the future of the ProMis study beyond the initial three years.

**Ask Garvan**

**Q:** I know that Garvan attracts PhD student from around the world. How many overseas PhD students are currently at Garvan?

**A:** We currently have around 100 PhD students at Garvan. 24 of these students are international, and represent 21 different countries from all over the globe including China, Mexico, Nigeria and Finland, to name just a few. At Garvan we greatly value the experience of international students, and fostering an internationally collaborative environment as it is without a doubt a driving force in the advancement of medical research.

**Q:** How do you recruit international PhD students?

**A:** We recruit international students usually via positions advertised on our website or through existing collaborations between their University and our researchers. We also host international undergraduate students who spend up to a year working with one of our research groups as part of their undergraduate degree.

Unfortunately, with fewer scholarships available, the application process for international students is extremely competitive. However, we would love to welcome more international students in the future as they have proven to be very talented and important contributors to the life of the Institute as a whole.

**In Celebration**

- John Friend’s 70th Birthday
- Jock Montgomery’s 90th Birthday
- Barbara Solomon’s 60th Birthday
- Gillian Whan’s 80th Birthday
**Staff Profile: Lisa Moncur**

Can you give us a brief outline of your recent work history?

I have been fortunate to work in science most of my working life, beginning at age sixteen as a casual lab assistant for the University of Sydney while finishing school, then studying a degree in biological science. As a qualified microbiologist and biotechnologist, I worked for two Australian biotechnology companies involved with human therapeutics and animal vaccines. Before joining Garvan I was developing rapid diagnostic products for food pathogen testing, as well as coordinating health and safety for a small company.

What do you enjoy doing in your spare time?

Any outdoor activities such as bike riding, bush walking and kayaking. I have also recently been scuba diving and jet skiing in Fiji. My adventurous parents took the family on a year-long world trip when I was a teenager and that began a great passion for travel and sightseeing. At the moment I am discovering South East Asia and more of Australia. In my down time I love to read and usually have two or three books on the go at once.

What inspires you about Garvan's work?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

Can you give us a brief outline of your recent work history?

I have been fortunate to work in science most of my working life, beginning at age sixteen as a casual lab assistant for the University of Sydney while finishing school, then studying a degree in biological science. As a qualified microbiologist and biotechnologist, I worked for two Australian biotechnology companies involved with human therapeutics and animal vaccines. Before joining Garvan I was developing rapid diagnostic products for food pathogen testing, as well as coordinating health and safety for a small company.

What do you enjoy doing in your spare time?

Any outdoor activities such as bike riding, bush walking and kayaking. I have also recently been scuba diving and jet skiing in Fiji. My adventurous parents took the family on a year-long world trip when I was a teenager and that began a great passion for travel and sightseeing. At the moment I am discovering South East Asia and more of Australia. In my down time I love to read and usually have two or three books on the go at once.

What inspires you about Garvan's work?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?

I love working for an organisation that is so well-respected and recognised for its medical research achievements. Everyone has been personally touched in some way by a disease that Garvan is researching, and I get a real sense of job satisfaction from being part of the progress towards improving future health outcomes. I admire the great dedication and commitment that Garvan researchers have for their work, particularly in the current climate of funding uncertainty.

What are your future goals or aspirations?
In Memoriam November 2014 to January 2015.
Donations have been made in memory of:

<table>
<thead>
<tr>
<th>Surname</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Hando</td>
<td>Adrian Notley</td>
</tr>
<tr>
<td>Joanne J Haney</td>
<td>Raimo Enso Nuto</td>
</tr>
<tr>
<td>Nancy June Heath</td>
<td>Kim O’Connor</td>
</tr>
<tr>
<td>Carolina Hoecher Pizarro</td>
<td>John Patterson</td>
</tr>
<tr>
<td>Evi Ioannou</td>
<td>Penelope Paul</td>
</tr>
<tr>
<td>Ludvik Kanturek</td>
<td>Glenys Elaine Payne</td>
</tr>
<tr>
<td>Maria Kenyon</td>
<td>Barry Peters</td>
</tr>
<tr>
<td>Anne Kidman</td>
<td>Patricia June Peters</td>
</tr>
<tr>
<td>Maggie King</td>
<td>Peter Poteri</td>
</tr>
<tr>
<td>Glen Stephen Kowalik</td>
<td>Helen Psarakis</td>
</tr>
<tr>
<td>Engelbert Martin Kromwky</td>
<td>Mary Quinless</td>
</tr>
<tr>
<td>Geoffrey Lane</td>
<td>Colleen Rabu</td>
</tr>
<tr>
<td>Alyson Latter</td>
<td>Juan Ramirez</td>
</tr>
<tr>
<td>Daryl L Levy</td>
<td>Robert John Rice</td>
</tr>
<tr>
<td>Grace Lewis</td>
<td>Alan Sansum</td>
</tr>
<tr>
<td>Julia May Linyard</td>
<td>Ian Douglas Shailer</td>
</tr>
<tr>
<td>Truong Luu</td>
<td>Jeffrey Shepherd</td>
</tr>
<tr>
<td>Moira K Lye</td>
<td>Kevin Simmons</td>
</tr>
<tr>
<td>Tim &amp; Andrew Lynch</td>
<td>Jose Simoes</td>
</tr>
<tr>
<td>Mrs Mackinnon</td>
<td>Susan Sinclair</td>
</tr>
<tr>
<td>Margherita &amp; Michele</td>
<td>Charlie Smith</td>
</tr>
<tr>
<td>Maldarella</td>
<td>Donald Matthew Smith</td>
</tr>
<tr>
<td>Kathleen McKenzie</td>
<td>Kate Welsh</td>
</tr>
<tr>
<td>Janet McKie</td>
<td>Beryl Agnes Wilmot</td>
</tr>
<tr>
<td>Anthony McLaughlin</td>
<td>Joan Margaret Wilson</td>
</tr>
<tr>
<td>Frances McNamara</td>
<td>Nick Wilson</td>
</tr>
<tr>
<td>Robert McWilliam</td>
<td>John Wright</td>
</tr>
<tr>
<td>Elizabeth Metcalfe</td>
<td>Danuta Zmitrovicz</td>
</tr>
<tr>
<td>Maureen Morrison</td>
<td>Asmah</td>
</tr>
<tr>
<td>Alison Nation</td>
<td>Shirley</td>
</tr>
<tr>
<td>Joseph N Nicol</td>
<td></td>
</tr>
</tbody>
</table>

BE PART OF PROGRESS

My Contact Details

<table>
<thead>
<tr>
<th>Title</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Surname
Address
Suburb State Postcode
Daytime Phone
Email
Garvan Supporter Number (if known)

Please Send Me Further Information About:

☐ Giving to Garvan in my will (strictly confidential)
☐ Volunteering with Garvan
☐ Giving regularly to Garvan through my bank account

Please Change My Communications:

☐ I no longer wish to receive this breakthrough newsletter
☐ I only wish to receive breakthrough by email
☐ I only wish to receive appeal mailings in May/June
☐ I do not wish to receive any appeal mailings

My Gift Details

Yes! I want to help Garvan make progress with a gift of

☐ $50 ☐ $100 ☐ $250 ☐ $500 ☐ $1000 ☐ Gift of choice $______

☐ My cheque/money order made payable to Garvan Research Foundation is enclosed

☐ OR Please deduct the above amount ☐ once ☐ monthly ☐ annually

from my ☐ Visa ☐ MasterCard ☐ Amex ☐ Diners

Card Number ___________________________ Expiry Date ____________

Cardholder’s Name ___________________________

Signature ___________________________

Donations of $2 and above are tax deductible.

Please use this coupon if you would like to make a donation to Garvan’s breakthrough medical research, or if you would like further information. We would love to hear from you.

Coming Up

Garvan public seminars
Friday 17 July – Type 1 and type 2 diabetes

Wednesday 9 September – Genomics and the revolution in medical research

Bookings for Garvan’s free public seminars are essential. Please call 1300 73 66 77 (weekdays, 9am to 5pm), or visit www.garvan.org.au/get-involved/events

Young Garvan events
Thursday 16 April – Young Garvan Forum – Not just surviving, thriving. To register, visit www.giving.garvan.org.au/young-garvan-forum
Saturday 18 July – Young Garvan All Ribbons Ball – Check the Garvan website for details in the coming weeks.

Clinical Studies

Pre-diabetes study

We are looking for healthy male volunteers who have close relatives with type 2 diabetes for a study investigating the role of the autonomic nervous system activity in the development of the disease. The study involves visiting the Garvan Institute in Darlinghurst for one morning during working hours. If you are willing, aged 50 to 60 years and healthy, please contact Lynne (02) 9295 8231 or Dorit (02) 9295 8309 or email crf@garvan.org.au (St Vincent’s HREC Ref 12/102).

Brown fat and blood pressure study

Brown fat is a special kind of fat which burns fat in the body. We are looking for volunteers who have high blood pressure to participate in a trial investigating the effect of a medication on brown fat. Participants must be aged 18 to 45 years and currently on one blood pressure medication. For further information please contact Dr Paul Lee (02) 9295 8416 or email p.lee@garvan.org.au (St Vincent’s HREC Ref 14/SVH/105).

Pre-diabetes study

We are looking for healthy male volunteers who have close relatives with type 2 diabetes for a study investigating the role of the autonomic nervous system activity in the development of the disease. The study involves visiting the Garvan Institute in Darlinghurst for one morning during working hours. If you are willing, aged 50 to 60 years and healthy, please contact Lynne (02) 9295 8231 or Dorit (02) 9295 8309 or email crf@garvan.org.au (St Vincent’s HREC Ref 12/102).

Brown fat and blood pressure study

Brown fat is a special kind of fat which burns fat in the body. We are looking for volunteers who have high blood pressure to participate in a trial investigating the effect of a medication on brown fat. Participants must be aged 18 to 45 years and currently on one blood pressure medication. For further information please contact Dr Paul Lee (02) 9295 8416 or email p.lee@garvan.org.au (St Vincent’s HREC Ref 14/SVH/105).